Yogaros Gold 75mg/10mg/75mg Capsule is a combination pharmaceutical formulation containing Aspirin (75mg), Rosuvastatin (10mg), and Clopidogrel (75mg), indicated for the prevention and management of cardiovascular diseases. Aspirin, a well-known antiplatelet agent, inhibits cyclooxygenase enzymes, thereby reducing thromboxane A2 synthesis and preventing platelet aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels, contributing to the stabilization of atherosclerotic plaques and reduction of cardiovascular risk. Clopidogrel, another antiplatelet agent, selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, preventing platelet activation and aggregation. The synergistic action of these three active ingredients makes Yogaros Gold suitable for patients at high risk of thrombotic events, including those with a history of myocardial infarction, stroke, or peripheral arterial disease. This combination therapy aids in reducing the incidence of major adverse cardiovascular events by targeting multiple pathways involved in thrombosis and lipid metabolism. Yogaros Gold should be administered under medical supervision, with careful monitoring for potential adverse effects such as bleeding, myopathy, or hepatic dysfunction. It is contraindicated in patients with active bleeding, hypersensitivity to any component, or severe liver impairment.